123 related articles for article (PubMed ID: 106732)
1. In vitro and in vivo production of chemotactic inhibitors by tumor cells.
Cohen MC; Brozna JP; Ward PA
Am J Pathol; 1979 Mar; 94(3):603-14. PubMed ID: 106732
[TBL] [Abstract][Full Text] [Related]
2. Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor.
Fioretti F; Fradelizi D; Stoppacciaro A; Ramponi S; Ruco L; Minty A; Sozzani S; Garlanda C; Vecchi A; Mantovani A
J Immunol; 1998 Jul; 161(1):342-6. PubMed ID: 9647242
[TBL] [Abstract][Full Text] [Related]
3. Failure of anti-T cell monoclonal antibodies to prevent acute tumor allograft rejection is associated with their inability to deplete or inactivate T cells at the site of rejection.
Rakhmilevich AL
Transplantation; 1994 Jul; 58(1):72-80. PubMed ID: 7913562
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppression induced in vitro by mastocytoma tumor cells and cell-free extracts.
Kamo I; Patel C; Kateley J; Friedman H
J Immunol; 1975 Jun; 114(6):1749-56. PubMed ID: 805176
[TBL] [Abstract][Full Text] [Related]
5. Antileukotactic properties of tumor cells.
Brozna JP; Ward PA
J Clin Invest; 1975 Sep; 56(3):616-23. PubMed ID: 239965
[TBL] [Abstract][Full Text] [Related]
6. [Effects of humoral factors of the mastocytoma P815 cells on the formation of allospecific killers in mixed culture of lymphocytes and their cytotoxic activity].
Medvedev AE; Dostman U; Flegel' A
Biull Eksp Biol Med; 1989 Aug; 108(8):224-6. PubMed ID: 2529921
[TBL] [Abstract][Full Text] [Related]
7. Characterization of macrophage chemotaxins in tumor cell cultures and comparison with lymphocyte-derived chemotactic factors.
Meltzer MS; Stevenson MM; Leonard EJ
Cancer Res; 1977 Mar; 37(3):721-5. PubMed ID: 837372
[TBL] [Abstract][Full Text] [Related]
8. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
Sensi M; Orosz CG; Bach FH
J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
[TBL] [Abstract][Full Text] [Related]
9. Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
Fallarino F; Uyttenhove C; Boon T; Gajewski TF
J Immunol; 1996 Feb; 156(3):1095-100. PubMed ID: 8557984
[TBL] [Abstract][Full Text] [Related]
10. Generation of a complement-derived chemotactic factor for tumor cells in experimentally induced peritoneal exudates and its effect on the local metastasis of circulating tumor cells.
Orr FW; Mokashi S; Delikatny J
Am J Pathol; 1982 Jul; 108(1):112-8. PubMed ID: 7091299
[TBL] [Abstract][Full Text] [Related]
11. [Humoral mechanisms of the membrano-toxic effects of mastocytoma P815 and leukemia EL4 cells].
Medvedev AE; Fuks BB
Biull Eksp Biol Med; 1989 Aug; 108(8):194-6. PubMed ID: 2508789
[TBL] [Abstract][Full Text] [Related]
12. [Humoral mechanisms of in vitro inhibition of mouse lymphocyte immunoreactivity by mastocytoma P815 cells].
Medvedev AE
Biull Eksp Biol Med; 1988 Jun; 105(6):701-3. PubMed ID: 2968820
[TBL] [Abstract][Full Text] [Related]
13. Further studies on the C5-derived chemotactic factor for tumor cells.
Romualdez AG; Ward PA
Prog Clin Biol Res; 1976; 9():65-71. PubMed ID: 193134
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of a tumor-specific T suppressor factor from a T cell hybridoma.
Steele JK; Stammers AT; Levy JG
J Immunol; 1985 Apr; 134(4):2767-78. PubMed ID: 2579156
[TBL] [Abstract][Full Text] [Related]
15. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
Germain RN; Williams RM; Benacerraf B
Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
[TBL] [Abstract][Full Text] [Related]
16. Circulating levels of IL-10 are critically related to growth and rejection patterns of murine mastocytoma cells.
Grohmann U; Silla S; Belladonna ML; Bianchi R; Orabona C; Puccetti P; Fioretti MC
Cell Immunol; 1997 Nov; 181(2):109-19. PubMed ID: 9398398
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro antitumor activity expressed by cells of concomitantly immune mice.
Tuttle RL; Knick VC; Stopford CR; Wolberg G
Cancer Res; 1983 Jun; 43(6):2600-5. PubMed ID: 6133611
[TBL] [Abstract][Full Text] [Related]
18. Quantitative studies of the growth and rejection of allogeneic tumour cells in mouse cerebrospinal fluid. Elimination in the absence of H-2 differences.
Doherty PC; Zinkernagel RM
Clin Exp Immunol; 1975 Feb; 19(2):355-66. PubMed ID: 813923
[TBL] [Abstract][Full Text] [Related]
19. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
